表紙
市場調查報告書

肝細胞癌(HCC)- 市場洞察,流行病學,預測 2028年

Hepatocellular carcinoma (HCC) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 534788
出版日期 內容資訊 英文 233 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肝細胞癌(HCC)- 市場洞察,流行病學,預測 2028年 Hepatocellular carcinoma (HCC) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 233 Pages
簡介

肝細胞癌(HCC),是最常見的原發性肝細胞癌症。肝細胞癌(HCC)是第5大癌症,其發生率由於B型及C型肝炎病毒感染的擴大在全世界增加。主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的肝細胞癌(HCC)的2017年的罹患數為10萬5,785人,同年的市場規模18億4,170萬美元估計。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的肝細胞癌(HCC)市場相關調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,各市場區隔的罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 肝細胞癌(HCC)市場概要

  • 肝細胞癌(HCC)的分佈(實在數值)
  • 肝細胞癌(HCC)的分佈(預測值)

第3章 疾病背景和概要:肝細胞癌(HCC)

  • 簡介
  • 症狀
  • 肝細胞癌的病期分類
  • 病因和危險因素
  • 病理生理學
  • 診斷
  • 診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 人口與預測參數
  • 主要7個國家的肝細胞癌的總罹患數

第5章 肝細胞癌(HCC)的流行病學:各國

  • 美國
    • 肝細胞癌(HCC)的總罹患數
    • 進展肝細胞癌(HCC)的罹患數
    • 肝細胞癌(HCC)的罹患數:性別
    • 肝細胞癌(HCC)的患病數:各病因
  • 歐盟5國
    • 德國
      • 肝細胞癌(HCC)的總罹患數
      • 進展肝細胞癌(HCC)的罹患數
      • 肝細胞癌(HCC)的罹患數:性別
      • 肝細胞癌(HCC)的患病數:各病因
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 肝細胞癌(HCC)的總罹患數
    • 肝細胞癌(HCC)的罹患數:2次各類型
    • 肝細胞癌(HCC)的罹患數:性別
    • 肝細胞癌(HCC)的患病數:各病期

第6章 治療的實踐

  • 治療目標
  • NCCN臨床診療指南為基礎治療流程
  • 肝細胞癌的治療的AASLD指南
  • HCC管理指南:歐洲醫療腫瘤學會(ESMO)
  • 早期及中期HCC的管理
  • 進展疾病的管理
  • 跟蹤、長期的影響、存活率

第7章 未滿足需求

第8章 貢獻組織

第9章 已上市治療藥

  • Nexavar:Bayer HealthCare
    • 產品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Miripla:大日本住友製藥
  • Opdivo:Bristol-Myers Squibb
  • Pembrolizumab (Keytruda):Merck & Co.
  • Stivarga:Bayer Pharma
  • Ramucirumab (Cyramza):Eli Lilly and Co.
  • Cabometyx:Exelixis Inc.
  • Lenvima:Merck/Eisai

第10章 新藥

  • 新藥分析
    • Tislelizumab (BGB-A317):BeiGene
    • Durvalumab (Imfinzi):Astra Zeneca
    • Milciclib:Tiziana Life Sciences
  • 聯合治療分析
  • 第三階段肝細胞癌臨床實驗的失敗

第11章 其他的有力候補藥

  • Namodenoson (CF 102):Can-Fite BioPharma
  • Capmatinib:Eli Lilly and Co.
  • Palbociclib: Pfizer
  • ENMD2076: CASI Pharmaceuticals
  • HCC011: Tera Bio-Pharma

第12章 個案研究

  • 切除無能的肝細胞癌
  • 青年成人的肝細胞癌

第13章 主要7個國家的肝細胞癌(HCC)市場分析

  • 主要調查結果
  • 主要7個國家的整體市場規模
  • 主要7個國家的市場規模:各治療線

第14章 各國市場預測

  • 美國的市場預測
  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療線
    • 市場規模:各一線藥物
    • 市場規模:各二線藥物
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

第18章 調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0348

DelveInsight's 'Hepatocellular carcinoma (HCC)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HCCs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hepatocellular carcinoma (HCC) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Hepatocellular carcinoma (HCC) - Disease Understanding and Treatment Algorithm

Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. It is a malignant tumor of hepatocytes, may exhibit any or all of the cytologic and/or architectural characteristics of hepatocellular differentiation, along with features of malignancy. Identification of intercellular bile and/or canaliculi are diagnostic of the cellular origin of the tumor. Hepatocellular Carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of Hepatitis B and C virus infection.

The DelveInsight Hepatocellular carcinoma (HCC) market report gives the thorough understanding of the Hepatocellular carcinoma by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatocellular carcinoma in the US, Europe and Japan.

Hepatocellular carcinoma Epidemiology

The Hepatocellular carcinoma (HCC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Incidence Cases of HCC, Advance Cases of HCC, Gender Specific Incident Cases of HCC, Incidence of HCC based on Aetiology and Incidence of HCC by BCLC stages) scenario of Hepatocellular carcinoma (HCC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of Incident cases of Hepatocellular carcinoma (HCC) in 7 MM was found to be 105,785 in the year 2017. 

Hepatocellular carcinoma Drug Chapters

This segment of the Hepatocellular carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment is generally recommended at early stage HCC and may not be recommended to treat patients with later stages of disease. These treatments are surgery, radiofrequency ablation, percutaneous ethanol injection, and radiation therapy. Surgical resection, transplantation, ablation, transarterial chemoembolization, and the tyrosine-kinase inhibitors sorafenib, lenvatinib, and regorafenib are the treatments with proven survival benefit. Systemic chemotherapy has marginal activity with associated toxicity and no survival benefit.

Hepatocellular carcinoma Market Outlook

The Hepatocellular carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Hepatocellular carcinoma in 7MM was found to be USD 1,841.7 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of HCC, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Hepatocellular carcinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatocellular carcinoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hepatocellular carcinoma Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Hepatocellular carcinoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Hepatocellular carcinoma market
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatocellular carcinoma market
  • To understand the future market competition in the Hepatocellular carcinoma market.

Table of Contents

1. Key Insights

2. Hepatocellular Carcinoma Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Hepatocellular Carcinoma in 2017
  • 2.2. Market Share (%) Distribution of Hepatocellular Carcinoma in 2028

3. Disease Background and Overview: Hepatocellular Carcinoma

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Staging of Hepatocellular Carcinoma
    • 3.3.1. Okuda Stage
    • 3.3.2. French Classification
    • 3.3.3. CLIP Score
    • 3.3.4. CUPI Score
    • 3.3.5. TNM Stage
    • 3.3.6. JIS Staging
    • 3.3.7. BCLC Staging System
  • 3.4. Etiology and Risk Factors
  • 3.5. Pathophysiology
    • 3.5.1. HCC progression and driver genes
    • 3.5.2. Molecular Pathways involved in HCC
  • 3.6. Diagnosis
  • 3.7. Diagnostic Guidelines
    • 3.7.1. American Association for the Study of Liver Diseases (AASLD) practice guidelines for HCC surveillance and diagnosis
    • 3.7.2. European Association for the Study of the Liver (EASL)-European Organization for Research and Treatment of Cancer (EORTC) practice guidelines for HCC surveillance and diagnosis
    • 3.7.3. Japanese evidence-based clinical practice guidelines for HCC
    • 3.7.4. NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Total Diagnosed Incident Cases of HCC in 7MM

5. Country Wise-Epidemiology of HCC

  • 5.1. The United States
    • 5.1.1. Total Diagnosed Incident cases of HCC in the United States
    • 5.1.2. Advance Stage Cases of HCC in the United States
    • 5.1.3. Gender Specific Incident Cases of HCC in the United States
    • 5.1.4. Incidence of HCC based on Aetiology in the United States
  • 5.2. EU5 Countries
  • 5.3. Germany
    • 5.3.1. Total Diagnosed Incident cases of HCC in Germany
    • 5.3.2. Advance Stage Cases of HCC in Germany
    • 5.3.3. Gender Specific Incident Cases of HCC in Germany
    • 5.3.4. Incidence of HCC based on Aetiology in Germany
  • 5.4. France
    • 5.4.1. Total Diagnosed Incident cases of HCC in France
    • 5.4.2. Advance Stage Cases of HCC in France
    • 5.4.3. Gender Specific Incident Cases of HCC in France
    • 5.4.4. Incidence of HCC based on Aetiology in France
  • 5.5. Italy
    • 5.5.1. Total Diagnosed Incident cases of HCC in Italy
    • 5.5.2. Advance Stage Cases of HCC in Italy
    • 5.5.3. Gender Specific Incident Cases of HCC in Italy
    • 5.5.4. Incidence of HCC based on Aetiology in Italy
  • 5.6. Spain
    • 5.6.1. Total Diagnosed Incident cases of HCC in Spain
    • 5.6.2. Advance Stage Cases of HCC in Spain
    • 5.6.3. Gender Specific Incident Cases of HCC in Spain
    • 5.6.4. Incidence of HCC based on Aetiology in Spain
  • 5.7. United Kingdom
    • 5.7.1. Total Diagnosed Incident cases of HCC in the United Kingdom
    • 5.7.2. Advance Stage Cases of HCC in the United Kingdom
    • 5.7.3. Gender Specific Incident Cases of HCC in the United Kingdom
    • 5.7.4. Incidence of HCC based on Aetiology in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Total Diagnosed Incident cases of HCC in Japan
    • 5.8.2. Advance Stage Cases of HCC in Japan
    • 5.8.3. Gender Specific Incident Cases of HCC in Japan
    • 5.8.4. Incidence of HCC based on Aetiology in Japan

6. Treatment Practices

  • 6.1. Treatment Goals
  • 6.2. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment
  • 6.3. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma
    • 6.3.1. Recommendations
  • 6.4. Management guidelines for HCC: European Society for Medical Oncology (ESMO)
  • 6.5. Management of Early and Intermediate HCC
  • 6.6. Management of Advance Disease
  • 6.7. Follow-up, long-term implications & survivorship

7. Unmet Needs

8. Organizations contributing towards HCC

9. Marketed Drug Analysis

  • 9.1. Nexavar: Bayer HealthCare
    • 9.1.1. Drug Description
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Generic Availability
    • 9.1.4. Clinical Development
    • 9.1.5. Safety and Efficacy
    • 9.1.6. Product Profile
  • 9.2. Miripla: Sumitomo Dainippon Pharma
    • 9.2.1. Drug Description
    • 9.2.2. Regulatory Milestones
    • 9.2.3. Clinical Development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile
  • 9.3. Opdivo: Bristol-Myers Squibb
    • 9.3.1. Drug Description
    • 9.3.2. Regulatory Milestones
    • 9.3.3. Clinical Development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile
  • 9.4. Pembrolizumab (Keytruda): Merck & Co.
    • 9.4.1. Drug Description
    • 9.4.2. Regulatory Milestones
    • 9.4.3. Clinical Development
    • 9.4.4. Safety and Efficacy
    • 9.4.5. Product Profile
  • 9.5. Stivarga: Bayer Pharma
    • 9.5.1. Drug Description
    • 9.5.2. Regulatory Milestones
    • 9.5.3. Generic Availability
    • 9.5.4. Clinical Development
    • 9.5.5. Safety and Efficacy
    • 9.5.6. Product Profile
  • 9.6. Ramucirumab (Cyramza): Eli Lilly and Co.
    • 9.6.1. Product Description
    • 9.6.2. Other Developmental Activities
    • 9.6.3. Clinical Development
    • 9.6.4. Safety and Efficacy
    • 9.6.5. Product Profile
  • 9.7. Cabometyx: Exelixis Inc.
    • 9.7.1. Product Description
    • 9.7.2. Other Developmental Activities
    • 9.7.3. Clinical Development
    • 9.7.4. Safety and Efficacy
    • 9.7.5. Product Profile
  • 9.8. Lenvima: Merck/Eisai
    • 9.8.1. Drug Description
    • 9.8.2. Regulatory Milestones
    • 9.8.3. Clinical Development
    • 9.8.4. Safety and Efficacy
    • 9.8.5. Product Profile

10. Emerging Therapies

  • 10.1. Emerging Drugs Analysis
    • 10.1.1. Tislelizumab (BGB-A317): BeiGene
    • 10.1.2. Durvalumab (Imfinzi): Astra Zeneca
    • 10.1.3. Milciclib: Tiziana Life Sciences
  • 10.2. Combinational Drugs Analysis
  • 10.3. Failure in Phase III Clinical trials for Hepatocellular Carcinoma

11. Other Promising Candidates

  • 11.1. Namodenoson (CF 102): Can-Fite BioPharma
    • 11.1.1. Product Description
    • 11.1.2. Other Developmental Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Safety and Efficacy
    • 11.1.5. Product Profile
  • 11.2. Capmatinib: Eli Lilly and Co.
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. Palbociclib: Pfizer
    • 11.3.1. Product Description
    • 11.3.2. Clinical Development
    • 11.3.3. Safety and Efficacy
    • 11.3.4. Product Profile
  • 11.4. ENMD2076: CASI Pharmaceuticals
    • 11.4.1. Product Description
    • 11.4.2. Other Developmental Activities
    • 11.4.3. Clinical Development
    • 11.4.4. Safety and Efficacy
    • 11.4.5. Product Profile
  • 11.5. HCC011: Tera Bio-Pharma
    • 11.5.1. Product Description
    • 11.5.2. Other Developmental Activities
    • 11.5.3. Clinical Development
    • 11.5.4. Product Profile

12. Case Studies

  • 12.1. Unresectable Hepatocellular Carcinoma
  • 12.2. Hepatocellular Carcinoma in a Young Adult

13. Hepatocellular Carcinoma [HCC]: 7MMMarket Analysis

  • 13.1. Key Findings
  • 13.2. Total Market Size of Hepatocellular Carcinoma (HCC) in 7MM
  • 13.3. 7MM Market Size of HCC by Line of Therapies

14. Market Outlook by Country

  • 14.1. The United States: Market Outlook
  • 14.2. United States Market Size
    • 14.2.1. Total Market size of Hepatocellular carcinoma [HCC]
    • 14.2.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.2.3. Market Size by First Line of Therapies
    • 14.2.4. Market Size by Second Line of Therapies
  • 14.3. EU-5 Countries: Market Outlook
  • 14.4. Germany Market Size
    • 14.4.1. Total Market size of Hepatocellular Carcinoma
    • 14.4.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.4.3. Market Size by First Line of Therapies
    • 14.4.4. Market Size by Second Line of Therapies
  • 14.5. France Market Size
    • 14.5.1. Total Market size of Hepatocellular Carcinoma
    • 14.5.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.5.3. Market Size by First Line of Therapies
    • 14.5.4. Market Size by Second Line of Therapies
  • 14.6. Italy Market Size
    • 14.6.1. Total Market size of Hepatocellular Carcinoma
    • 14.6.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.6.3. Market Size by First Line of Therapies
    • 14.6.4. Market Size by Second Line of Therapies
  • 14.7. Spain Market Size
    • 14.7.1. Total Market size of Hepatocellular Carcinoma
    • 14.7.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.7.3. Market Size by First Line of Therapies
    • 14.7.4. Market Size by Second Line of Therapies
  • 14.8. United Kingdom Market Size
    • 14.8.1. Total Market size of Hepatocellular Carcinoma
    • 14.8.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.8.3. Market Size by First Line of Therapies
    • 14.8.4. Market Size by Second Line of Therapies
  • 14.9. Japan: Market Outlook
    • 14.9.1. Total Market size of Hepatocellular Carcinoma
    • 14.9.2. Hepatocellular Carcinoma Market Size by Line of Therapies
    • 14.9.3. Market Size by First Line of Therapies
    • 14.9.4. Market Size by Second Line of Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

18. Report Methodology

  • 18.1. Sources Used

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Tables

  • Table 1: Staging systems along with the prognostic variables used in staging systems in Hepatocellular carcinoma
  • Table 2: Risk factors and recommended surveillance for HCC according to etiology
  • Table 3: Major recurrent molecular aberrations observed in advanced HCC
  • Table 4: Total Incident Cases of HCC in 7MM (2017-2028)
  • Table 5: Total Diagnosed Incident Cases of HCC in the United States (2017-2028)
  • Table 6: Advance Stage Cases of HCC in the United States (2017-2028)
  • Table 7: Gender Specific Incident Cases of HCC in the United States (2017-2028)
  • Table 8: Incidence of HCC based on Aetiology in the United States (2017-2028)
  • Table 9: Incidence of HCC by BCLC stages in the United States (2017-2028)
  • Table 10: Total Diagnosed Incident Cases of HCC in Germany (2017-2028)
  • Table 11: Advance Stage Cases of HCC in Germany (2017-2028)
  • Table 12: Gender Specific Incident Cases of HCC in Germany (2017-2028)
  • Table 13: Incidence of HCC based on Aetiology in Germany (2017-2028)
  • Table 14: Incidence of HCC by BCLC stages in Germany (2017-2028)
  • Table 15: Total Diagnosed Incident Cases of HCC in France (2017-2028)
  • Table 16: Advance Stage Cases of HCC in France (2017-2028)
  • Table 17: Gender Specific Incident Cases of HCC in France (2017-2028)
  • Table 18: Incidence of HCC based on Aetiology in France (2017-2028)
  • Table 19: Incidence of HCC by BCLC stages in France (2017-2028)
  • Table 20: Total Diagnosed Incident Cases of HCC in Italy (2017-2028)
  • Table 21: Advance Stage Cases of HCC in Italy (2017-2028)
  • Table 22: Gender Specific Incident Cases of HCC in Italy (2017-2028)
  • Table 23: Incidence of HCC based on Aetiology in Italy (2017-2028)
  • Table 24: Incidence of HCC by BCLC stages in Italy (2017-2028)
  • Table 25: Total Diagnosed Incident Cases of HCC in Spain (2017-2028)
  • Table 26: Advance Stage Cases of HCC in Spain (2017-2028)
  • Table 27: Gender Specific Incident Cases of HCC in Spain (2017-2028)
  • Table 28: Incidence of HCC based on Aetiology in Spain (2017-2028)
  • Table 29: Incidence of HCC by BCLC stages in Spain (2017-2028)
  • Table 30: Total Diagnosed Incident Cases of HCC in the United Kingdom (2017-2028)
  • Table 31: Advance Stage Cases of HCC in the United Kingdom (2017-2028)
  • Table 32: Gender Specific Incident Cases of HCC in the United Kingdom (2017-2028)
  • Table 33: Incidence of HCC based on Aetiology in the United Kingdom (2017-2028)
  • Table 34: Incidence of HCC by BCLC stages in the United Kingdom (2017-2028)
  • Table 35: Total Diagnosed Incident Cases of HCC in Japan (2017-2028)
  • Table 36: Advance Stage Cases of HCC in Japan (2017-2028)
  • Table 37: Gender Specific Incident Cases of HCC in Japan (2017-2028)
  • Table 38: Incidence of HCC based on Aetiology in Japan (2017-2028)
  • Table 39: Incidence of HCC by BCLC stages in Japan (2017-2028)
  • Table 40: Organizations contributing toward Hepatocellular Carcinoma
  • Table 41: Marketed Drug Analysis
  • Table 42: Nexavar, Clinical Trial Description, 2019
  • Table 43: Miripla, Clinical Trial Description, 2019
  • Table 44: Opdivo Clinical Trial Description, 2019
  • Table 45: Keytruda Clinical Trial Description, 2019
  • Table 46: Regorafenib, Clinical Trial Description, 2019
  • Table 47: Ramucirumab, Clinical Trial Description, 2019
  • Table 48: Cabozantinib, Clinical Trial Description, 2019
  • Table 49: Lenvima, Clinical Trial Description, 2019
  • Table 50: Emerging Drugs Analysis
  • Table 51: BGB-A317, Clinical Trial Description, 2019
  • Table 52: Durvalumab, Clinical Trial Description, 2019
  • Table 53: Milciclib, Clinical Trial Description, 2019
  • Table 54: Combinational Drug Analysis
  • Table 55: Clinical Trial Description, 2019
  • Table 56: CF-102, Clinical Trial Description, 2019
  • Table 57: INC280, Clinical Trial Description, 2019
  • Table 58: PD-0332991, Clinical Trial Description, 2018
  • Table 59: ENMD2076, Clinical Trial Description, 2019
  • Table 60: 7MM Market Size of HCC in USD Million (2017-2028)
  • Table 61: 7MM HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 62: The US Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 63: The U.S. HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 64: The US HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 65: The US HCC market size by Second Line of Therapies in USD Million (2017-2028)
  • Table 66: Germany Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 67: Germany HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 68: Germany HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 69: Germany HCC market size by Second Line of Therapies in USD Million (2017-2028)
  • Table 70: France Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 71: France HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 72: France HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 73: The France HCC market size by Second Line of Therapies in USD Million (2017-2028)
  • Table 74: The Italy Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 75: Italy HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 76: Italy HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 77: The Italy HCC market size by Second Line of Therapies in USD Million (2017-2028)
  • Table 78: The Spain Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 79: Spain HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 80: Spain HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 81: Spain HCC market size by Second Line of Therapies in USD Million (2017-2028)
  • Table 82: The UK Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 83: UK HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 84: The UK HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 85: The UK HCC market size by Second Line of Therapies in USD Million (2017-2028)
  • Table 86: The Japan Market Hepatocellular Carcinoma in USD Million (2017-2028)
  • Table 87: Japan HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Table 88: Japan HCC market size by First Line of Therapies in USD Million (2017-2028)
  • Table 89: The Japan HCC market size by Second Line of Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: BCLC staging system and therapeutic strategy
  • Figure 2: HCC progression and driver genes
  • Figure 3: Molecular targeted therapies for HCC and their target Signaling pathways
  • Figure 4: PD1 & PD-L1 Signaling pathway
  • Figure 5: PD-1/PD-L1 Met pathway
  • Figure 6: FGFR pathway
  • Figure 7: FGFR pathway in Tumor proliferation & apoptosis
  • Figure 8: HGF/cMET Pathway in HCC
  • Figure 9: Multi-receptor Pathway in HCC
  • Figure 10: List of Biomarkers for HCC & Liver Cirrhosis
  • Figure 11: List of Biomarkers for HCV & HCB related HCC
  • Figure 12: List of Prognostic & Diagnostic Biomarkers for HCC in Blood
  • Figure 13: List of Prognostic & Diagnostic Biomarkers for HCC in Blood
  • Figure 14: AASLD practice guidelines for HCC surveillance and diagnosis
  • Figure 15: EASL-EORTC practice guidelines for HCC surveillance and diagnosis
  • Figure 16: Japanese evidence-based clinical practice guidelines for HCC: surveillance and diagnostic algorithm
  • Figure 17:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
  • Figure 18:NCCN Clinical practice Guidelines - When HCC is confirmed (continued from figure 7)
  • Figure 19: Total Diagnosed Incident Cases of HCC in 7MM (2017-2028)
  • Figure 20: Total Diagnosed Incident Cases of HCC in the United States (2017-2028)

Figure21: Advance Stage Cases of HCC in the United States (2017-2028)

  • Figure 22: Gender Specific Incident Cases of HCC in the United States (2017-2028)
  • Figure 23: Incidence of HCC based on Aetiology in the United States (2017-2028)
  • Figure 24: Incidence of HCC by BCLC stages in the United States (2017-2028)
  • Figure 25: Total Diagnosed Incident Cases of HCC in Germany (2017-2028)

Figure26: Advance Stage Cases of HCC in Germany (2017-2028)

  • Figure 27: Gender Specific Incident Cases of HCC in Germany (2017-2028)
  • Figure 28: Incidence of HCC based on Aetiology in Germany (2017-2028)
  • Figure 29: Incidence of HCC by BCLC stages in Germany (2017-2028)
  • Figure 30: Total Diagnosed Incident Cases of HCC in France (2017-2028)

Figure31: Advance Stage Cases of HCC in France (2017-2028)

  • Figure 32: Gender Specific Incident Cases of HCC in France (2017-2028)
  • Figure 33: Incidence of HCC based on Aetiology in France (2017-2028)
  • Figure 34: Incidence of HCC by BCLC stages in France (2017-2028)
  • Figure 35: Total Diagnosed Incident Cases of HCC in Italy (2017-2028)

Figure36: Advance Stage Cases of HCC in Italy (2017-2028)

  • Figure 37: Gender Specific Incident Cases of HCC in Italy (2017-2028)
  • Figure 38: Incidence of HCC based on Aetiology in Italy (2017-2028)
  • Figure 39: Incidence of HCC by BCLC stages in Italy (2017-2028)
  • Figure 40: Total Diagnosed Incident Cases of HCC in Spain (2017-2028)

Figure41: Advance Stage Cases of HCC in Spain (2017-2028)

  • Figure 42: Gender Specific Incident Cases of HCC in Spain (2017-2028)
  • Figure 43: Incidence of HCC based on Aetiology in Spain (2017-2028)
  • Figure 44: Incidence of HCC by BCLC stages in Spain (2017-2028)
  • Figure 45: Total Diagnosed Incident Cases of HCC in the United Kingdom (2017-2028)

Figure46: Advance Stage Cases of HCC in the United Kingdom (2017-2028)

  • Figure 47: Gender Specific Incident Cases of HCC in the United Kingdom (2017-2028)
  • Figure 48: Incidence of HCC based on Aetiology in the United Kingdom (2017-2028)
  • Figure 49: Incidence of HCC by BCLC stages in the United Kingdom (2017-2028)
  • Figure 50: Total Diagnosed Incident Cases of HCC in Japan (2017-2028)

Figure51: Advance Stage Cases of HCC in Japan (2017-2028)

  • Figure 52: Gender Specific Incident Cases of HCC in Japan (2017-2028)
  • Figure 53: Incidence of HCC based on Aetiology in Japan (2017-2028)
  • Figure 54: Incidence of HCC by BCLC stages in Japan (2017-2028)
  • Figure 55:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
  • Figure 56: Treatment algorithm according to NCC guidelines
  • Figure 57: Unmet Needs for Hepatocellular Carcinoma
  • Figure 58: 7MM Market Size of HCC in USD Million (2017-2028)
  • Figure 59: 7MM Market Size of HCC by Line of Therapies in USD Million (2017-2028)
  • Figure 60: Market Size of HCC in the United States, USD Millions (2017-2028)
  • Figure 61: The U.S. HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 62: The U.S. market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 63: The U.S. market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 64: Market Size of HCC in the Germany, USD Millions (2017-2028)
  • Figure 65: Germany HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 66: Germany market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 67: Germany market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 68: Market Size of HCC in France, USD Millions (2017-2028)
  • Figure 69: France HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 70: France market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 71: The France market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 72: Market Size of HCC in Italy, USD Millions (2017-2028)
  • Figure 73: The Italy HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 74: The Italy market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 75: The Italy market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 76: Market Size of HCC in Spain, USD Millions (2017-2028)
  • Figure 77: The Spain HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 78: Spain market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 79: Spain market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 80: Market Size of HCC in UK, USD Millions (2017-2028)
  • Figure 81: The UK HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 82: The UK market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 83: The UK market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 84: Market Size of HCC in Japan, USD Millions (2017-2028)
  • Figure 85: The Japan HCC Market Size by Line of therapies in USD Million (2017-2028)
  • Figure 86: Japan market size of HCC by First Line of therapies in USD Million (2017-2028)
  • Figure 87: Japan market size of HCC by Second Line of therapies in USD Million (2017-2028)
  • Figure 88: Market Drivers for Hepatocellular Carcinoma
  • Figure 89: Market Barriers for Hepatocellular Carcinoma
Back to Top